New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’
December 09, 2022 at 10:50 AM EST
Lecanemab, the drug being tested by Biogen and Eisai, was found to have a modest benefit to patients in a Phase 3 study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|